Real-World Data Shows Low-Dose Tirzepatide Effective for Obesity Over Six Months

Obesity is a complex, chronic disease affecting millions globally, significantly increasing the risk of conditions like type 2 diabetes, cardiovascular disease, and certain cancers. Tirzepatide, a novel dual GLP-1 and GIP receptor agonist, has demonstrated remarkable efficacy in controlled clinical trials for both type 2 diabetes and weight management. However, there remains a critical need for real-world evidence to understand its effectiveness, patient persistence, and safety profile when used at low-to-moderate doses in diverse adult populations with obesity outside of highly controlled research settings. This study aims to fill that gap by observing outcomes in routine clinical practice.

Over the six-month observation period, patients treated with Tirzepatide experienced a significant and clinically meaningful average body weight reduction of 10.5% from their baseline weight (p<0.001). This translated to an average decrease in body mass index (BMI) of -3.8 kg/m² (p<0.001). > Crucially, the study revealed that 85% of participants achieved at least 5% body weight loss, a threshold often associated with significant health benefits, and an impressive 43% achieved 10% or more body weight loss, demonstrating robust real-world efficacy even at low-to-moderate doses. Treatment persistence was notably high, with 78% of patients continuing Tirzepatide therapy for the full six months, indicating good tolerability and patient satisfaction. Adverse events were predominantly mild-to-moderate gastrointestinal issues (e.g., nausea, constipation), consistent with known profiles, and rarely led to treatment discontinuation (<5%).